Maxim Group Reaffirms Hold Rating for Matinas BioPharma (NYSEAMERICAN:MTNB)

Maxim Group reiterated their hold rating on shares of Matinas BioPharma (NYSEAMERICAN:MTNB) in a research report sent to investors on Thursday morning, Marketbeat Ratings reports.

Matinas BioPharma Stock Performance

Shares of NYSEAMERICAN MTNB opened at $0.58 on Thursday. Matinas BioPharma has a 12-month low of $0.54 and a 12-month high of $21.50. The company has a market capitalization of $2.92 million, a P/E ratio of -0.11 and a beta of 1.73.

Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its earnings results on Wednesday, August 14th. The company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02).

Institutional Investors Weigh In On Matinas BioPharma

A number of hedge funds have recently made changes to their positions in the business. Towercrest Capital Management bought a new position in Matinas BioPharma in the 2nd quarter worth approximately $299,000. Alliance Wealth Management Group bought a new position in shares of Matinas BioPharma in the second quarter worth $299,000. Finally, Highbridge Capital Management LLC acquired a new position in shares of Matinas BioPharma during the second quarter valued at $1,685,000. Institutional investors own 11.77% of the company’s stock.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.